153 related articles for article (PubMed ID: 38619081)
21. The diversity of human papillomavirus infection among human immunodeficiency virus-infected women in Yunnan, China.
Zhang HY; Fei MD; Jiang Y; Fei QY; Qian H; Xu L; Jin YN; Jiang CQ; Li HX; Tiggelaar SM; Smith JS; Sahasrabuddhe VV; Qiao YL
Virol J; 2014 Dec; 11():202. PubMed ID: 25481842
[TBL] [Abstract][Full Text] [Related]
22. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.
Vintermyr OK; Iversen O; Thoresen S; Quint W; Molijn A; de Souza S; Rosillon D; Holl K
Gynecol Oncol; 2014 May; 133(2):159-66. PubMed ID: 24631451
[TBL] [Abstract][Full Text] [Related]
23. HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong's largest independent pathology laboratory.
Jiang L; Tian X; Peng D; Zhang L; Xie F; Bi C; Wang R; Wang J; Qi D
PLoS One; 2019; 14(1):e0210311. PubMed ID: 30653566
[TBL] [Abstract][Full Text] [Related]
24. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
[TBL] [Abstract][Full Text] [Related]
26. Clinical and epidemiological features of high-risk human papillomavirus infection in patients with cervical intraepithelial lesions.
Ding YQ; Yu J; Wang RQ; Sang L
BMC Womens Health; 2023 Sep; 23(1):468. PubMed ID: 37658312
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
[TBL] [Abstract][Full Text] [Related]
28. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
29. Risks for cervical abnormalities in women with non-16/18 high-risk human papillomavirus infections in south Shanghai, China.
Wang X; Wu S; Li Y
J Med Virol; 2021 Nov; 93(11):6355-6361. PubMed ID: 34232523
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
[TBL] [Abstract][Full Text] [Related]
31. Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses.
Arroyo Mühr LS; Eklund C; Lagheden C; Eriksson T; Pimenoff VN; Gray P; Lehtinen M; Dillner J
J Infect Dis; 2022 Sep; 226(7):1195-1199. PubMed ID: 35535025
[TBL] [Abstract][Full Text] [Related]
32. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
33. Concurrent Infection With Multiple Human Papillomavirus Types Among Unvaccinated and Vaccinated 17-Year-Old Norwegian Girls.
Laake I; Feiring B; Jonassen CM; Pettersson JHO; Frengen TG; Kirkeleite IØ; Trogstad L
J Infect Dis; 2022 Sep; 226(4):625-633. PubMed ID: 33205203
[TBL] [Abstract][Full Text] [Related]
34. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.
Wang R; Guo XL; Wisman GB; Schuuring E; Wang WF; Zeng ZY; Zhu H; Wu SW
BMC Infect Dis; 2015 Jul; 15():257. PubMed ID: 26142044
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer.
Onuki M; Matsumoto K; Satoh T; Oki A; Okada S; Minaguchi T; Ochi H; Nakao S; Someya K; Yamada N; Hamada H; Yoshikawa H
Cancer Sci; 2009 Jul; 100(7):1312-6. PubMed ID: 19432906
[TBL] [Abstract][Full Text] [Related]
36. Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18-25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016.
Welby S; Rosillon D; Feng Y; Borys D
Expert Rev Vaccines; 2022 Mar; 21(3):407-413. PubMed ID: 34939897
[TBL] [Abstract][Full Text] [Related]
37. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China.
Zhang J; Zhang D; Yang Z; Wang X; Wang D
BMC Cancer; 2020 May; 20(1):443. PubMed ID: 32429919
[TBL] [Abstract][Full Text] [Related]
38. [Multi-center cross-sectional study on type-specific human papillomavirus infection among Chinese women].
Zhao Y; Zhao F; Hu S; Chen W; Chen F; Cui J; Liu B; Zhang W; Zhang X; Pan Q; Qiao Y
Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Dec; 36(12):1351-6. PubMed ID: 26850387
[TBL] [Abstract][Full Text] [Related]
39. Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18.
Fu Xi L; Schiffman M; Ke Y; Hughes JP; Galloway DA; He Z; Hulbert A; Winer RL; Koutsky LA; Kiviat NB
Int J Cancer; 2017 Apr; 140(8):1747-1756. PubMed ID: 28052328
[TBL] [Abstract][Full Text] [Related]
40. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
